-+ 0.00%
-+ 0.00%
-+ 0.00%

RBC Capital Maintains Outperform on Contineum Therapeutics, Raises Price Target to $23

Benzinga·07/31/2026 18:43:32
Listen to the news
RBC Capital analyst Brian Abrahams maintains Contineum Therapeutics (NASDAQ:CTNM) with a Outperform and raises the price target from $22 to $23.